Stemness Characteristics of Fibrolamellar Hepatocellular Carcinoma: Immunohistochemical Analysis with Comparisons to Conventional Hepatocellular Carcinoma

被引:1
|
作者
Zenali, Maryam J. [1 ,2 ]
Tan, Dongfeng [3 ]
Li, Wei [1 ,2 ]
Dhingra, Sadhna [1 ,2 ]
Brown, Robert E. [1 ,2 ]
机构
[1] Univ Texas Hlth Sci Ctr Houston, Dept Pathol, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, Dept Lab Med, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源
关键词
fibrolamellar hepatocellular carcinoma; cancer stem cells; CD133; CD44; PPAR-gamma; beta-catenin; Ki-67; Skp2; CELLS; CANCER; EXPRESSION; LIVER; THERAPY; CD133; PROLIFERATION; RESISTANCE; CAPACITY; SURVIVAL;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The involvement of cancer stem cells (CSC) in tumorigenesis has been studied in several malignancies, but their presence in fibrolamellar hepatocellular carcinoma (FLHCC) has not previously been evaluated. General characteristics of "stemness" include the expression of putative stem cell antigens, reduced cell cycle progression, and limited functional differentiation or dedifferentiation under the influence of the microenvironment. Immunohistochemical probes applied to 8 archival cases of FLHCC vis-a-vis contiguous non-neoplastic parenchyma, which was present in 5 cases, revealed such stemness characteristics by showing: (a) stem cell antigens, with moderate to intense expression of CD133 in the cytoplasm (6 of 8 FLHCC cases and comprising >40% of the tumoral areas) and of CD44 on the plasmalemmal aspect (7 of 8 FLHCC cases and comprising 50 to 95% of the tumor cells), vs foci of such overexpressions in only 1 of 5 of the contiguous liver parenchyma (p = 0.053 and p = 0.015, respectively); (b) limited G1 to S phase progression (<1% of tumor cells with nuclear S phase kinase-associated protein [Skp]2 expression); and (c) dedifferentiation or reduced functional differentiation in the form of minimal to absent expression of a differentiation-associated marker, peroxisomal proliferator-activator receptor (PPAR)-gamma in tumoral nuclei and loss of plasmalemmal expression of beta-catenin in 6 of 8 FLHCC cases vs expression of these proteins in the non-neoplastic, differentiated hepatocytes in 5 of 5 and 4 of 5 cases, respectively, in contiguous liver parenchyma (p <0.01 and p = 0.053, respectively). In contrast, only 1 of 11 cases of well-differentiated, conventional hepatocellular carcinoma (HCC) showed mild to moderate expression of CD133 in the cytoplasm, but with the majority (8 of 11) showing occasional nuclear expression. Similarly, only 3 of 11 cases of conventional HCC expressed plasmalemmal CD44. Notably, 11 of 11 cases of conventional HCC expressed beta-catenin on the plasmalemmal aspect of the tumor cells, and 3 of 11 showed nuclear translocation. These findings in conventional HCC were significantly different from those in FLHCC (p = 0.003, 0.009, and 0.0005, respectively). This study provides evidence of stemness in FLHCC and discusses the implications of stemness in the histogenesis of FLHCC vs conventional, well-differentiated HCC.
引用
收藏
页码:126 / 134
页数:9
相关论文
共 50 条
  • [31] Claudins and tricellulin in fibrolamellar hepatocellular carcinoma
    Patonai, Attila
    Erdelyi-Belle, Boglarka
    Korompay, Anna
    Somoracz, Aron
    Straub, Beate K.
    Schirmacher, Peter
    Kovalszky, Ilona
    Lotz, Gabor
    Kiss, Andras
    Schaff, Zsuzsa
    VIRCHOWS ARCHIV, 2011, 458 (06) : 679 - 688
  • [32] Imaging Features of Fibrolamellar Hepatocellular Carcinoma
    Ganeshan, Dhakshinamoorthy
    Szklaruk, Janio
    Kundra, Vikas
    Kaseb, Ahmed
    Rashid, Asif
    Elsayes, Khaled
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2014, 202 (03) : 544 - 552
  • [33] Fibrolamellar hepatocellular carcinoma in children and adolescents
    Katzenstein, HM
    Krailo, MD
    Malogolowkin, MH
    Ortega, JA
    Qu, WC
    Douglass, EC
    Feusner, JH
    Reynolds, M
    Quinn, JJ
    Newman, K
    Finegold, MJ
    Haas, JE
    Sensel, MG
    Castleberry, RP
    Bowman, LC
    CANCER, 2003, 97 (08) : 2006 - 2012
  • [34] Intracranial metastasis in fibrolamellar hepatocellular carcinoma
    Hammond, William J.
    Lalazar, Gadi
    Saltsman, James A.
    Farber, Benjamin A.
    Danzer, Enrico
    Sherpa, Tshering C.
    Banda, Charles D.
    Andolina, Jeffrey R.
    Karimi, Sasan
    Brennan, Cameron W.
    Torbenson, Michael S.
    La Quaglia, Michael P.
    Simon, Sanford M.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (04)
  • [35] Molecular analysis of the pediatric cancer fibrolamellar hepatocellular carcinoma
    Simon, Elana P.
    Honeyman, Joshua N.
    Darcy, David G.
    Rosenberg, Brad R.
    Lim, Iris I.
    Murphy, Jennifer M.
    Farber, Ben
    Lalazar, Gadi
    Freije, Catherine
    La Quaglia, Michael P.
    Simon, Sanford M.
    CANCER RESEARCH, 2015, 75
  • [36] Fibrolamellar hepatocellular carcinoma metastatic to the ovary
    Benito, V.
    Segura, J.
    Martinez, M. S.
    Arencibia, O.
    Lubrano, A.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2012, 32 (02) : 200 - U111
  • [37] Radiotherapy for metastatic fibrolamellar hepatocellular carcinoma
    Peacock, Justin G.
    Call, Jason A.
    Olivier, Kenneth R.
    RARE TUMORS, 2013, 5 (03) : 101 - 102
  • [38] IMAGING OF FIBROLAMELLAR HEPATOCELLULAR-CARCINOMA
    BRANDT, DJ
    JOHNSON, CD
    STEPHENS, DH
    WEILAND, LH
    AMERICAN JOURNAL OF ROENTGENOLOGY, 1988, 151 (02) : 295 - 299
  • [39] Hyperammonemic encephalopathy and fibrolamellar hepatocellular carcinoma
    Berger, Cintia
    Dimant, Pablo
    Hermida, Laura
    Paulin, Francisco
    Pereyra, Matias
    Tejo, Mariana
    MEDICINA-BUENOS AIRES, 2012, 72 (05) : 425 - 427
  • [40] Fibrolamellar hepatocellular carcinoma: a case report and gene analysis
    Watanabe, Akira
    Harimoto, Norifumi
    Saito, Hideyuki
    Kawabata-Iwakawa, Reika
    Seki, Takaomi
    Muranushi, Ryo
    Hoshino, Kouki
    Hagiwara, Kei
    Ishii, Norihiro
    Tsukagoshi, Mariko
    Igarashi, Takamichi
    Araki, Kenichiro
    Ikota, Hayato
    Ishige, Takashi
    Mimori, Koshi
    Shirabe, Ken
    SURGICAL CASE REPORTS, 2023, 9 (01)